C4 Therapeutics(CCCC.US)

Last Updated 19:00:00 ET
longbridge loading

C4 Therapeutics Realigns Finance Leadership After Officer Departure

Tip Ranks·
US
CCCC
-3.42%
US
IBB
+0.10%
US
FBT
+0.54%
Tip Ranks·
US
CCCC
-3.42%
US
IBB
+0.10%
US
FBT
+0.54%

Vishay Intertechnology, Eos Energy Enterprises, Tower Semiconductor And Other Big Stocks Moving Higher On Wednesday

benzinga_article·
US
CCCC
-3.42%
US
EOSEW
0.00%
US
NXT
-5.47%
benzinga_article·
US
CCCC
-3.42%
US
EOSEW
0.00%
US
NXT
-5.47%

Earnings Scheduled For May 12, 2026

benzinga_article·
US
CCCC
-3.42%
US
SION
-3.98%
US
VSTS
-2.71%
benzinga_article·
US
CCCC
-3.42%
US
SION
-3.98%
US
VSTS
-2.71%

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Unusual Whales·
US
CCCC
-3.42%
US
XBI
-0.69%
US
BIB
+0.05%
Unusual Whales·
US
CCCC
-3.42%
US
XBI
-0.69%
US
BIB
+0.05%

Jefferies Remains a Buy on C4 Therapeutics (CCCC)

Tip Ranks·
US
PBE
+0.11%
US
IBB
+0.10%
US
BBH
+0.68%
Tip Ranks·
US
PBE
+0.11%
US
IBB
+0.10%
US
BBH
+0.68%

Roche and C4 Therapeutics to advance degrader-antibody conjugates research

Pharmaceutical Technology·
US
XLV
+1.10%
US
CCCC
-3.42%
US
FBT
+0.54%
Pharmaceutical Technology·
US
XLV
+1.10%
US
CCCC
-3.42%
US
FBT
+0.54%

Should Roche’s Bet on Degrader-Antibody Conjugates and New HIV/Hepatitis Test Reshape Roche (SWX:ROP)?

Simplywall·
US
IBB
+0.10%
US
SBIO
-1.24%
US
IHI
+1.00%
Simplywall·
US
IBB
+0.10%
US
SBIO
-1.24%
US
IHI
+1.00%
© 2026 Longbridge｜Disclaimer